Bruce C Casto
Overview
Explore the profile of Bruce C Casto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
294
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Oghumu S, Casto B, Ahn-Jarvis J, Weghorst L, Maloney J, Geuy P, et al.
Front Immunol
. 2017 Nov;
8:1325.
PMID: 29109723
Oral cancer continues to be a significant public health problem worldwide. Recently conducted clinical trials demonstrate the ability of black raspberries (BRBs) to modulate biomarkers of molecular efficacy that supports...
2.
Knobloch T, Uhrig L, Pearl D, Casto B, Warner B, Clinton S, et al.
Cancer Prev Res (Phila)
. 2015 Dec;
9(2):159-71.
PMID: 26701664
Black raspberries (BRB) demonstrate potent inhibition of aerodigestive tract carcinogenesis in animal models. However, translational clinical trials evaluating the ability of BRB phytochemicals to impact molecular biomarkers in the oral...
3.
Warner B, Casto B, Knobloch T, Accurso B, Weghorst C
Oral Surg Oral Med Oral Pathol Oral Radiol
. 2014 Dec;
118(6):674-83.
PMID: 25457886
Objective: To evaluate the preclinical efficacy of topical administration of freeze-dried black raspberries (BRBs) to inhibit the progression of premalignant oral lesions and modulate biomarkers of cancer development in high...
4.
Harris R, Casto B, Harris Z
World J Clin Oncol
. 2014 Oct;
5(4):677-92.
PMID: 25302170
Cohesive scientific evidence from molecular, animal, and human investigations supports the hypothesis that constitutive overexpression of cyclooxygenase-2 (COX-2) is a ubiquitous driver of mammary carcinogenesis, and reciprocally, that COX-2 blockade...
5.
Casto B, Knobloch T, Galioto R, Yu Z, Accurso B, Warner B
Anticancer Res
. 2013 Nov;
33(11):4757-66.
PMID: 24222110
Background/aim: Oral cancer represents approximately 2.5% of all cancers in the United States, with five- and 10-year survival rates of 62% and 51%. In the present study, lyophilized strawberries (LS)...
6.
Pereira M, Warner B, Knobloch T, Weghorst C, Lubet R, Steele V, et al.
Int J Cancer
. 2011 Dec;
131(6):1277-86.
PMID: 22161747
Atorvastatin and suberoylanilide hydroxamic acid (SAHA) were evaluated for chemoprevention of mouse lung tumors. In Experiment 1, lung tumors were induced by vinyl carbamate in strain A/J mice followed by...
7.
Casto B, Pereira M
Anticancer Res
. 2011 Oct;
31(10):3279-84.
PMID: 21965737
Background: Concurrent and sequential administration of combinations of budesonide, bexarotene, suberoylanilide hydroxamic acid (SAHA) and atorvastatin were evaluated in A/J mice for prevention of lung tumors initiated by 4-(methylnitrosoamino)-1-(3-pyridyl)-1-butanol, NNK)....
8.
Casto B, Sharma S, Fisher J, Knobloch T, Agrawal A, Weghorst C
J Health Care Poor Underserved
. 2009 Feb;
20(1):274-85.
PMID: 19202262
Oral cancer accounts for 2.3% of malignancies in the U.S. and has one of the lowest five-year survival rates. An examination of oral cancer in Appalachia was motivated by the...
9.
Kresty L, Mallery S, Knobloch T, Li J, Lloyd M, Casto B, et al.
Cancer Epidemiol Biomarkers Prev
. 2008 Nov;
17(11):3179-87.
PMID: 18990760
Proliferative verrucous leukoplakia (PVL) represents a rare but highly aggressive form of oral leukoplakia with > 70% progressing to malignancy. Yet, PVL remains biologically and genetically poorly understood. This study...
10.
Li J, Warner B, Casto B, Knobloch T, Weghorst C
Mol Carcinog
. 2008 Feb;
47(10):733-8.
PMID: 18247379
The prevalence of p16(INK4A)/Cdkn2a genetic alterations in human oral cancers indicates that the p16 gene could be a potent and appropriate target for novel intervention. While chemically induced hamster cheek...